News | July 26, 2023
Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Good momentum in commercial CDMO business
CMOs showed an increasing reluctance to take on debt in 2022
The strategic acquisition demonstrates the company’s commitment to increasing OTC consumer convenience in eye care
Cytel excels at using proven quantitative techniques to transform real-world data into actionable insights
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
SHL Medical announces the acquisition of LCA Automation AG, a Swiss innovative automation solutions provider
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Subscribe To Our Newsletter & Stay Updated
